Drug Trial Radar · NCT03972722
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
89
Planned (sponsor's estimate)
Start
May 15, 2019
Primary completion
May 15, 2022
Study completion May 15, 2023
Sponsor
- Lead sponsor
- Guangzhou Gloria Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with recurrent or metastatic cervical cancer,and will be treated with GLS-010.
Conditions
- Cervical Cancer
Interventions
GLS-010Drug
Patients will be given 240mg GLS-010 every treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: within 27 Months after patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.